Literature DB >> 24655958

Outcome of lupus nephritis after entering into end-stage renal disease and comparison between different treatment modalities: a nationwide population-based cohort study in Taiwan.

M-J Wu1, Y-C Lo2, J-L Lan3, T-M Yu4, K-H Shu4, D-Y Chen5, H-C Ho6, C-H Lin7, S-N Chang7.   

Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) is not a rare disease among the Chinese and the incidence is higher in the female population. Lupus nephritis (LN) often develops in patients with SLE and may progress to end-stage renal disease (ESRD). Although there are studies that suggest postponement of the scheduling of kidney transplantation (KT) for these patients, there are still some other studies with conflicting results. Our study aimed to analyze the outcome of patients with LN after progression to ESRD and to try to elucidate whether deferral of KT is necessary in the Chinese population.
METHODS: We used the National Health Insurance Research Database to perform this cohort study. The study cohort was observed between 1998 and 2009 after being diagnosed as having SLE. The cases of SLE and ESRD were identified according to the catastrophic illness database.
RESULTS: In total, 1998 SLE patients with ESRD were identified. They received hemodialysis, peritoneal dialysis, or KT with the proportion of 82.1%, 9.8%, and 8.1%, respectively. The 1-year, 5-year, 10-year patient survival rates were best for those who underwent KT (100%, 98.1%, and 94.4%, respectively), followed by peritoneal dialysis (88.3%, 79.1%, and 76%, respectively), and hemodialysis (53.6%, 46.0%, and 41.6%, respectively). For those who underwent KT within 1 year after ESRD, no significant worse patient survival and graft survival were observed than those who underwent KT 1 year later.
CONCLUSION: KT provides a better survival benefit for SLE patients with ESRD than hemodialysis and peritoneal dialysis. No obvious clinical benefit of KT deferral was observed in our study and the deferral may not be necessary for our population. Crown
Copyright © 2014. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24655958     DOI: 10.1016/j.transproceed.2013.11.080

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

1.  Clinical outcomes of kidney transplants on patients with end-stage renal disease secondary to lupus nephritis, polycystic kidney disease and diabetic nephropathy.

Authors:  John Fredy Nieto-Ríos; Lina María Serna-Higuita; Sheila Alexandra Builes-Rodriguez; Ricardo Cesar Restrepo-Correa; Arbey Aristizabal-Alzate; Catalina Ocampo-Kohn; Angélica Serna-Campuzano; Natalia Cardona-Díaz; Nelson Darío Giraldo-Ramirez; Gustavo Adolfo Zuluaga-Valencia
Journal:  Colomb Med (Cali)       Date:  2016-03-30

2.  Systematic review and meta-analysis of clinical outcomes comparison between different initial dialysis modalities in end-stage renal disease patients due to lupus nephritis prior to renal transplantation.

Authors:  Joel Swai; Xiexiong Zhao; Julie-Raisa Noube; Gui Ming
Journal:  BMC Nephrol       Date:  2020-05-01       Impact factor: 2.388

3.  Comparison of mortality and its causes in patients with complicated systemic lupus erythematosus on hemodialysis versus peritoneal dialysis: A meta-analysis.

Authors:  Wenjun Gou; Yan Hong Tuo
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

4.  Propensity Score-Matched Analysis of the Survival Benefit from Kidney Transplantation in Patients with End-Stage Renal Disease.

Authors:  Ming-Ju Wu; Tung-Min Yu; Cheng-Li Lin; Chia-Hung Kao
Journal:  J Clin Med       Date:  2018-10-26       Impact factor: 4.241

Review 5.  Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations.

Authors:  Myrto Kostopoulou; Antonis Fanouriakis; Kim Cheema; John Boletis; George Bertsias; David Jayne; Dimitrios T Boumpas
Journal:  RMD Open       Date:  2020-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.